Background: Cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer. Treatment options for inoperable advanced cSCC cases are limited. The efficacy of anti-programmed cell death-1 (PD-1) monoclonal antibodies (mAb) has been reported recently in some patients with cSCC.
Objectives: To evaluate the efficacy of anti-PD-1 mAb in a case series of inoperable advanced cSCC and to analyse the efficacy of concurrent radiotherapy.
Materials And Methods: We retrospectively analysed the files of all patients with advanced inoperable cSCC treated with anti-PD-1 mAb and concurrent radiotherapy outside clinical trials in our skin cancer centre before December 31, 2017.
Results: A total of four patients with locally or regionally advanced cSCC were identified. All patients received pembrolizumab at 2 mg/kg every three weeks and concurrent radiotherapy. Two patients who received pembrolizumab as first-line therapy with concurrent radiotherapy (one with skull and leptomeningeal invasion and one with rapidly progressing regional cSCC) had a complete response, allowing treatment discontinuation, without recurrence after a median of 11 months off treatment. All other patients experienced progressive disease. The median progression-free survival and overall survival were 14.4 and 15.6 months, respectively. No toxicity was observed.
Conclusion: There appears to be a place for pembrolizumab as first-line treatment for unresectable or advanced cSCC. Further studies are needed to evaluate concomitant radiotherapy with anti-PD1 antibodies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/ejd.2019.3671 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant Cetuximab Leading to a Complete Pathologic Response in Locally Advanced Lip Squamous Cell Carcinoma.
Cureus
December 2024
Oncology and Hematology, Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, USA.
Vermillion lip squamous cell carcinoma (SCC) is a rare cancer, currently grouped together with the cutaneous lip under the cutaneous squamous cell carcinoma (cSCC) system. Herein, we present a case of an 81-year-old male with locally advanced lower lip SCC involving the vermillion who achieved a complete pathologic response to neoadjuvant cetuximab after the failure of the programed cell death protein-1 (PD-1) inhibitor, cemiplimab. He was followed with clinical observation, with special attention to skin/mucosal surfaces.
View Article and Find Full Text PDFRecommendations for the management of cutaneous squamous cell carcinoma: a systematic multidisciplinary Delphi consensus approach.
Clin Transl Oncol
December 2024
Fundación ECO (Excelencia y Calidad en Oncología), Madrid, Spain.
Background: There are gaps and unanswered questions in clinical guidelines regarding several aspects of the management of patients with cutaneous squamous cell carcinoma (cSCC).
Methods: A scientific committee of ten cSCC specialists in Spain (dermatology, medical oncology, oral and maxillofacial surgery, plastic surgery, and radiotherapy) used ADAPTE methodology to develop recommendations by: (i) identifying clinical questions not fully answered by clinical practice guidelines; (ii) systematically reviewing the literature (published between November 2017 and July 2023 in PubMed and the Cochrane database) and grading the evidence (using Oxford levels); (iii) developing recommendations and assessing those with no consensus among the scientific committee or with evidence level 3-5 or strength of recommendation under C or D in a two-round Delphi method; and (iv) developing the final recommendations in the form of answers to key clinical questions, grading the strength of recommendation. An external group of 32 experts plus the members of the committee participated in both Delphi rounds, evaluating the appropriateness and need of the recommendations.
The genomic landscape of cutaneous squamous cell carcinoma in Japan.
J Dermatol
December 2024
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Comprehensive studies of the genetic profiles of cutaneous squamous cell carcinoma (cSCC) in Japanese patients have been lacking, although an understanding of these profiles is crucial for improving treatment outcomes. Since 2019, comprehensive genomic profiling (CGP) has been covered by Japan's health insurance, and the resulting data have been compiled into a comprehensive database by the country's Center for Cancer Genomics and Advanced Therapeutics (C-CAT). In this retrospective study, we used CGP data from the C-CAT database to analyze genomic characteristics of cSCC in Japanese patients.
View Article and Find Full Text PDFMycosis fungoides (MF), a form of cutaneous T-cell lymphoma (CTCL), increases the risk of other malignancies. A common and effective treatment for patients with MF is radiotherapy (RT), which itself also increases the risk of malignancies. One such malignancy that may result from both MF and RT is cutaneous squamous cell carcinoma (cSCC).
View Article and Find Full Text PDFPannexin 1 and pannexin 3 differentially regulate the cancer cell properties of cutaneous squamous cell carcinoma.
J Physiol
November 2024
Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
Pannexin (PANX) channels are present in skin and facilitate the movement of signalling molecules during cellular communication. PANX1 and PANX3 function in skin homeostasis and keratinocyte differentiation but were previously reduced in a small cohort of human cutaneous squamous cell carcinoma (cSCC) tumours compared to normal epidermis. In our study we used SCC-13 cells, limited publicly available RNA-seq data and a larger cohort of cSCC patient-matched samples to analyse PANX1 and PANX3 expression and determine the association between their dysregulation and the malignant properties of cSCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!